Detrimental effect of postnatal blockade of N-methyl-D-aspartate receptors on sensorimotor gating is reversed by neuroleptic drugs

Pharmacological Reports

Volumn 60, Issue 6, 2008, Pages 856-864

  Wedzony, Krzysztof ^a   Fijał, Katarzyna ^a   Maćkowiak, Marzena ^a   Chocyk, Agnieszka ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Developmental model of schizophrenia; Neuroleptic drugs; NMDA receptors; Sensorimotorgating

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RISPERIDONE; 2 AMINO 5 PHOSPHONOVALERIC ACID; 2-AMINO-4-METHYL-5-PHOSPHONO-3-PENTENOIC ACID; DOPAMINE RECEPTOR; DRUG DERIVATIVE; NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; FEMALE; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PERINATAL PERIOD; PREPULSE INHIBITION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; RECEPTOR BLOCKING; SENSORIMOTOR FUNCTION; STARTLE REFLEX; ANIMAL; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; SCHIZOPHRENIA; SENSORY GATING; WISTAR RAT;

2-AMINO-5-PHOSPHONOVALERATE; ANIMALS; ANTIPSYCHOTIC AGENTS; AUTORADIOGRAPHY; CLOZAPINE; DISEASE MODELS, ANIMAL; FEMALE; MALE; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE; RECEPTORS, N-METHYL-D-ASPARTATE; RISPERIDONE; SCHIZOPHRENIA; SENSORY GATING;

EID: 65249132364     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Akil M, Edgar CL, Pierri JN, Casali S, Lewis DA: Decreased density of tyrosine hydroxylase-immunoreactive axons in the entorhinal cortex of schizophrenic subjects. Biol Psychiatry, 2000, 47, 361-370.
2. Akil M, Pierri JN, Whitehead RE, Edgar CL, Mohila C, Sampson AR, Lewis DA: Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry, 1999, 156, 1580-1589.
3. al Amin HA, Schwarzkopf SB: Effects of the PCP analog dizocilpine on sensory gating: potential relevance to clinical subtypes of schizophrenia. Biol Psychiatry, 1996, 40, 744-754.
4. Bast T, Zhang W, Feldon J, White IM: Effects of MK801 and neuroleptics on prepulse inhibition: re-examination in two strains of rats. Pharmacol Biochem Behav, 2000, 67, 647-658.
5. Becker A, Peters B, Schroeder H, Mann T, Huether G, Grecksch G: Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia. Prog Neuro-psychopharmacol Biol Psychiatry, 2003, 27, 687-700.
6. Biała G, Kruk M: Amphetamine-induced anxiety-related behavior in animal models. Pharmacol Rep, 2007, 59, 636-644.
7. Braff DL, Geyer MA, Swerdlow NR: Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl), 2001, 156, 234-258.
8. Broadbelt K, Byne W, Jones LB: Evidence for a decrease in basilar dendrites of pyramidal cells in schizophrenic medial prefrontal cortex. Schizophr Res, 2002, 58, 75-81.
9. 2 dopamine receptor agonists and antagonists on prepulse inhibition of acoustic startle in the rat. Neuropsychopharmacology, 1995, 12, 139-145.
10. Carr DB, Sesack SR: Projections from the rat prefrontal cortex to the ventral tegmental area: target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. J Neurosci, 2000, 20, 3864-3873.
11. Di Pietro NC, Seamans JK: Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action. Pharmacopsychiatry, 2007, 40, Suppl 1, S27-S33.
12. Kalus P, Muller TJ, Zuschratter W, Senitz D: The dendritic architecture of prefrontal pyramidal neurons in schizophrenic patients. Neuroreport, 2000, 11, 3621-3625.
13. Kehrer C, Maziashvili N, Dugladze T, Gloveli T: Altered excitatory-inhibitory balance in the NMDA-hypofunction model of schizophrenia. Front Mol Neurosci, 2008, 1, 6.
14. Keith VA, Mansbach RS, Geyer MA: Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol Psychiatry, 1991, 30, 557-566.
15. Mansbach RS, Geyer MA, Braff DL: Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology (Berl), 1988, 94, 507-514.
16. Martinez ZA, Ellison GD, Geyer MA, Swerdlow NR: Effects of sustained phencyclidine exposure on sensorimotor gating of startle in rats. Neuropsychopharmacology, 1999, 21, 28-39.
17. Mitchell JB, Gratton A: Partial dopamine depletion of the prefrontal cortex leads to enhanced mesolimbic dopamine release elicited by repeated exposure to naturally reinforcing stimuli. J Neurosci, 1992, 12, 3609-3618.
18. Ouagazzal A, Grottick AJ, Moreau J, Higgins GA: Effect of LSD on prepulse inhibition and spontaneous behavior in the rat. A pharmacological analysis and comparison between two rat strains. Neuropsychopharmacology, 2001, 25, 565-575.
19. Powell CM, Miyakawa T: Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder? Biol Psychiatry, 2006, 59, 1198-1207.
20. Rasmussen K, Gates MR, Burger JE, Czachura JF: The novel atypical antipsychotic olanzapine, but not the CCK-B antagonist LY288513, blocks apomorphine-induced disruption of pre-pulse inhibition. Neurosci Lett, 1997, 222, 61-64.
21. Rogóz Z, Skuza G, Daniel WA, Wójcikowski J, Dudek D, Wróbel A: Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression. Pharmacol Rep, 2007, 59, 778-784.
22. Schneider M, Koch M: The cannabinoid agonist WIN 55,212-2 reduces sensorimotor gating and recognition memory in rats. Behav Pharmacol, 2002, 13, 29-37.
23. Sesack SR, Carr DB, Omelchenko N, Pinto A: Anatomical substrates for glutamate-dopamine interactions: evidence for specificity of connections and extrasynaptic actions. Ann N Y Acad Sci, 2003, 1003, 36-52.
24. Sipes TA, Geyer MA: 8-OH-DPAT disruption of prepulse inhibition in rats: reversal with (+)WAY 100,135 and localization of site of action. Psychopharmacology (Berl), 1995, 117, 41-48.
25. 2A receptors in the ventral pallidum. Brain Res, 1997, 761, 97-104.
26. Sipes TA, Geyer MA: Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats. Neuropharmacology, 1994, 33, 441-448.
27. 3 receptors are a common site of action for antipsychotic drugs: an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. Schizophr Bull, 2008, (in press).
28. Swerdlow NR, Braff DL, Geyer MA: Cross-species studies of sensorimotor gating of the startle reflex. Ann N Y Acad Sci, 1999, 877, 202-216.
29. Swerdlow NR, Braff DL, Geyer MA, Koob GF: Central dopamine hyperactivity in rats mimics abnormal acoustic startle response in schizophrenics. Biol Psychiatry, 1986, 21, 23-33.
30. Swerdlow NR, Braff DL, Masten VL, Geyer MA: Schizophrenic-like sensorimotor gating abnormalities in rats following dopamine infusion into the nucleus accumbens. Psychopharmacology (Berl), 1990, 101, 414-420.
31. Swerdlow NR, Geyer MA: Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia. Pharmacol Biochem Behav, 1993, 44, 741-744.
32. 3 receptors? Behav Pharmacol, 1998, 9, 445-455.
33. Wan FJ, Swerdlow NR: Intra-accumbens infusion of quinpirole impairs sensorimotor gating of acoustic startle in rats. Psychopharmacology (Berl), 1993, 113, 103-109.
34. Wan FJ, Swerdlow NR: Sensorimotor gating in rats is regulated by different dopamine-glutamate interactions in the nucleus accumbens core and shell subregions. Brain Res, 1996, 722, 168-176.
35. Wang C, McInnis J, Ross-Sanchez M, Shinnick-Gallagher P, Wiley JL, Johnson KM: Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience, 2001, 107, 535-550.
36. Wedzony K, Fijał K, Chocyk A: Blockade of NMDA receptors in postnatal period decreased density of tyrosine hydroxylase immunoreactive axonal arbors in the medial prefrontal cortex of adult rats. J Physiol Pharmacol, 2005, 56, 205-221.
37. Wedzony K, Fijał K, Maćkowiak M: Alterations in the dendritic morphology of prefrontal pyramidal neurons in adult rats after blockade of NMDA receptors in the postnatal period. Brain Res, 2005, 1062, 166-170.
38. Wedzony K, Fijał K, Maćkowiak M, Chocyk A, Zajaczkowski W: Impact of postnatal blockade of N-methyl-D-aspartate receptors on rat behavior: a search for a new developmental model of schizophrenia. Neuroscience, 2008, 153, 1370-1379.
39. Wedzony K, Gołembiowska K, Zazula M: Differential effects of CGP 37849 and MK-801, competitive and noncompetitive NMDA antagonists, with respect to the modulation of sensorimotor gating and dopamine out-flow in the prefrontal cortex of rats. Naunyn Schmiedebergs Arch Pharmacol, 1994, 350, 555-562.
40. 3 antagonists on PPI deficits induced by PD 128907 and apomorphine. Behav Brain Res, 2007, 182, 1-11.